CDK13: A Promising Drug Target and Biomarker for Cancer Treatment

Target Name: CDK13

NCBI ID: G8621

CDK13

CDK13: A Promising Drug Target and Biomarker for Cancer Treatment

CDK13 (CDK-13) is a gene that encodes for a protein known as cyclin D13, which plays a critical role in cell division and growth. CDK13 variants have been linked to various diseases, including cancer. The variant CDK13 has been shown to have potential as a drug target or biomarker in cancer treatment. In this article, we will explore the biology of CDK13, its association with cancer, and its potential as a drug target.

CDK13 Variants and Cancer

CDK13 variants have been implicated in the development and progression of various cancers, including breast, ovarian, and prostate cancers. Studies have shown that variants in the CDK13 gene are associated with poor prognosis in cancer patients. CDK13 variants have also been shown to contribute to the development of resistance to chemotherapy in cancer patients.

CDK13 as a Drug Target

CDK13 has been shown to be a potential drug target in cancer treatment. The cyclin D13 protein plays a critical role in cell division and growth, and its regulation is known to be involved in various cellular processes that are necessary for cancer growth. CDK13 has been shown to be involved in the development of cancer stem cells, which are cancer cells that have the ability to continuously self-renew and promote the growth of cancer.

CDK13 has also been shown to be involved in the development of resistance to chemotherapy in cancer patients. Studies have shown that CDK13 variants are associated with the development of resistance to chemotherapy in cancer patients, which can lead to a decrease in the effectiveness of chemotherapy and a higher risk of recurrence.

CDK13 as a Biomarker

CDK13 has also been shown to be a potential biomarker for cancer. The CDK13 gene has been shown to be expressed in various types of cancer, including breast, ovarian, and prostate cancers. Studies have shown that the expression of CDK13 is associated with the severity of cancer and the effectiveness of chemotherapy.

CDK13 has also been shown to be involved in the development of various types of cancer, including breast, ovarian, and prostate cancers. Studies have shown that CDK13 variants are associated with the development of these cancers and can contribute to their progression.

Conclusion

CDK13 is a gene that has been shown to play a critical role in the development and progression of various cancers, including breast, ovarian, and prostate cancers. CDK13 variants have also been shown to contribute to the development of cancer stem cells and the development of resistance to chemotherapy in cancer patients. Therefore, CDK13 has the potential as a drug target or biomarker for cancer treatment. Further studies are needed to fully understand the role of CDK13 in cancer biology and its potential as a drug target or biomarker.

Protein Name: Cyclin Dependent Kinase 13

Functions: Cyclin-dependent kinase which displays CTD kinase activity and is required for RNA splicing. Has CTD kinase activity by hyperphosphorylating the C-terminal heptapeptide repeat domain (CTD) of the largest RNA polymerase II subunit RPB1, thereby acting as a key regulator of transcription elongation. Required for RNA splicing, probably by phosphorylating SRSF1/SF2. Required during hematopoiesis. In case of infection by HIV-1 virus, interacts with HIV-1 Tat protein acetylated at 'Lys-50' and 'Lys-51', thereby increasing HIV-1 mRNA splicing and promoting the production of the doubly spliced HIV-1 protein Nef

The "CDK13 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDK13 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets